Schizophrenia News and Research

Latest Schizophrenia News and Research

NIH awards Salk Institute $4.5M to establish new Neuroscience Core Center

The National Institutes of Health has announced that the Salk Institute will receive $4.5 million to establish a Neuroscience Core Center, a new research center intended to accelerate brain research that lays the foundation for developing new ways to treat congenital brain defects and neurological diseases.

14 Oct 2011

Dual drug sneaks across the blood-brain barrier to fight HIV

In an advance toward eliminating pockets of infection in the brain that help make HIV disease incurable, scientists report the development of new substances that first plug the biological vacuum cleaner that prevents anti-HIV drugs from reaching the brain and then revert to an active drug to treat HIV.

14 Oct 2011

Scientists reprogram skin cells of patients with mental disorders into brain cells

For many poorly understood mental disorders, such as schizophrenia or autism, scientists have wished they could uncover what goes wrong inside the brain before damage ensues.

13 Oct 2011

Cannabis use leads to increased risk of depression in young people with specific genotype

Young people who are genetically vulnerable to depression should be extra careful about using cannabis: smoking cannabis leads to an increased risk of developing depressive symptoms.

10 Oct 2011

Lack of sleep during adolescence could lead to more than dragging, foggy teens

An ongoing lack of sleep during adolescence could lead to more than dragging, foggy teens, a University of Wisconsin-Madison study suggests.

10 Oct 2011

BDNF methionine variation increases risk of suicidal behaviour

A new study from the Centre for Addiction and Mental Health has found evidence that a specific gene is linked to suicidal behaviour, adding to our knowledge of the many complex causes of suicide. This research may help doctors one day target the gene in prevention efforts.

10 Oct 2011

Art, drama and dance may benefit dementia sufferers

While medical researchers continue the search for advanced diagnosis, prevention and treatment of dementia, a researcher at Royal Holloway, University of London is focusing on improving the experiences of those already suffering with the devastating disease for whom any cure would be too late.

7 Oct 2011

BDNF met variation gene linked to suicidal behaviour

7 Oct 2011

New $13.75M data-mining project to better understand factors behind mental disorders

Chicago will be home to a new $13.75 million project that will apply data mining methods to better understand the genetic and environmental factors behind neuropsychiatric disorders.

7 Oct 2011

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

A chemical component of the marijuana plant could prevent the onset of pain associated with drugs used in chemo therapy, particularly in breast cancer patients, according to researchers at Temple University's School of Pharmacy.

7 Oct 2011

New insight into mechanisms of hippocampal rhythms

A research team from Berlin, Munich and Haifa has presented new findings concerning the function of the hippocampus, a region of the brain that is important for memory formation.

7 Oct 2011

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes plc today announced the initiation of a phase 2b study of ALKS 37, an orally active, peripherally restricted opioid antagonist for the treatment of opioid-induced constipation.

3 Oct 2011

Jails are holding increasing numbers of mentally ill

The Atlanta Journal-Constitution reports that in Georgia more mentally ill people are locked away than are treated in state psychiatric hospitals. In other state news about mental health, Florida seeks to recoup $4 million from company that managed Medicaid mental health services, and Milwaukee considers bolstering services.

30 Sep 2011

AstraZeneca settles SEROQUEL XR patent infringement litigation

AstraZeneca today announced it has entered into a settlement agreement in its U.S. SEROQUEL XR patent infringement litigation against Handa Pharmaceuticals, LLC regarding Handa's proposed generic version of AstraZeneca's SEROQUEL XR extended-release tablets.

30 Sep 2011

New report finds little evidence to support off-label use of atypical antipsychotics

There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

29 Sep 2011

Experts to explore implications of mental disorders at 12th EMBL | EMBO conference

You are invited to attend the 12th joint EMBL | EMBO Science and Society Conference - Making sense of mental illness: biology, medicine and society. The conference takes place 4-5 November 2011 at the EMBL Advanced Training Centre, Heidelberg, Germany. Press registration is free.

28 Sep 2011

UCSF neuroscientist wins PECASE award for research into addiction

Linda Wilbrecht, PhD, a neuroscientist at the Ernest Gallo Clinic and Research Center at the University of California, San Francisco (UCSF), is one of 94 researchers named today by President Obama as a recipient of the Presidential Early Career Awards for Scientists and Engineers (PECASE).

28 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

Afraxis, a San Diego-based biotechnology company developing drugs to treat rare genetic diseases through the modulation of p21-activated kinase (PAK), announced today that it has been selected to participate in the National Institutes of Health's (NIH) Therapeutics for Rare and Neglected Disease (TRND) Program.

27 Sep 2011

Schizophrenia News and Research

Latest Schizophrenia News and Research

NIH awards Salk Institute $4.5M to establish new Neuroscience Core Center

Dual drug sneaks across the blood-brain barrier to fight HIV

Scientists reprogram skin cells of patients with mental disorders into brain cells

Cannabis use leads to increased risk of depression in young people with specific genotype

Lack of sleep during adolescence could lead to more than dragging, foggy teens

BDNF methionine variation increases risk of suicidal behaviour

Art, drama and dance may benefit dementia sufferers

BDNF met variation gene linked to suicidal behaviour

New $13.75M data-mining project to better understand factors behind mental disorders

Cannabidiol could prevent onset of pain associated with chemotherapy drugs

New insight into mechanisms of hippocampal rhythms

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Jails are holding increasing numbers of mentally ill

AstraZeneca settles SEROQUEL XR patent infringement litigation

New report finds little evidence to support off-label use of atypical antipsychotics

Experts to explore implications of mental disorders at 12th EMBL | EMBO conference

UCSF neuroscientist wins PECASE award for research into addiction

Benefits and harms vary among atypical antipsychotics for off-label use

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

Afraxis to participate in NIH's Therapeutics for Rare and Neglected Disease Program

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Schizophrenia News and Research

Latest Schizophrenia News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in